

# Hannah M Linden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/23125/publications.pdf>

Version: 2024-02-01

25  
papers

1,353  
citations

567281

15  
h-index

610901

24  
g-index

25  
all docs

25  
docs citations

25  
times ranked

1780  
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic hematopoietic cell transplantation in patients with a hematologic malignancy and a prior history of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 194, 507-516.	2.5	0
2	<sup>18</sup> F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2 <sup>-</sup> Metastatic Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, 184-190.	5.0	20
3	<sup>18</sup> F-fluorodeoxyglucose (FDG) PET or <sup>18</sup> F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	5.0	11
4	Determinants of Guideline-Discordant Breast Cancer Care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 61-70.	2.5	2
5	Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network. <i>Tomography</i> , 2020, 6, 60-64.	1.8	2
6	Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer <sup>†</sup> A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib. <i>Clinical Breast Cancer</i> , 2019, 19, e283-e296.	2.4	24
7	Test-Retest Reproducibility of <sup>18</sup> F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local Network. <i>Journal of Nuclear Medicine</i> , 2019, 60, 608-614.	5.0	21
8	Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e143-e149.	2.4	15
9	The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1219-1235.	0.8	30
10	Clinical Potential of Estrogen and Progesterone Receptor Imaging. <i>PET Clinics</i> , 2018, 13, 415-422.	3.0	30
11	Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 560-562.	5.0	10
12	Quantitative Imaging in Cancer Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 284-290.	7.0	106
13	Satisfaction with cancer care among American Indian and Alaska Natives in Oregon and Washington State: a qualitative study of survivor and caregiver perspectives. <i>Supportive Care in Cancer</i> , 2016, 24, 2437-2444.	2.2	11
14	Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 75S-80S.	5.0	43
15	The Value of Establishing the Quantitative Accuracy of PET/CT Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1133-1134.	5.0	8
16	Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. <i>Clinical Breast Cancer</i> , 2015, 15, e277-e285.	2.4	6
17	Effect of <sup>18</sup> F-FDG Uptake Time on Lesion Detectability in PET Imaging of Early-Stage Breast Cancer. <i>Tomography</i> , 2015, 1, 53-60.	1.8	12
18	Novel Methods and Tracers for Breast Cancer Imaging. <i>Seminars in Nuclear Medicine</i> , 2013, 43, 324-329.	4.6	52

#	ARTICLE	IF	CITATIONS
19	Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. <i>EJNMMI Research</i> , 2012, 2, 34.	2.5	27
20	Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4799-4805.	7.0	120
21	PET Tumor Metabolism in Locally Advanced Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: Value of Static versus Kinetic Measures of Fluorodeoxyglucose Uptake. <i>Clinical Cancer Research</i> , 2011, 17, 2400-2409.	7.0	94
22	Tumor Metabolism and Blood Flow Changes by Positron Emission Tomography: Relation to Survival in Patients Treated With Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4449-4457.	1.6	142
23	Attitudes Toward Participation in Breast Cancer Randomized Clinical Trials in the African American Community. <i>Cancer Nursing</i> , 2007, 30, 261-269.	1.5	59
24	Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2793-2799.	1.6	357
25	Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1806-14.	5.0	151